nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylnaltrexone—Naloxone—TLR4—melanoma	0.0328	0.655	CrCbGaD
Methylnaltrexone—Gastrointestinal perforation—Docetaxel—melanoma	0.0308	0.102	CcSEcCtD
Methylnaltrexone—Injection site reaction—Carmustine—melanoma	0.0124	0.0412	CcSEcCtD
Methylnaltrexone—Redness—Docetaxel—melanoma	0.0119	0.0395	CcSEcCtD
Methylnaltrexone—Erythema—Vemurafenib—melanoma	0.0103	0.0343	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00874	0.029	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Vemurafenib—melanoma	0.00827	0.0274	CcSEcCtD
Methylnaltrexone—Skin disorder—Vemurafenib—melanoma	0.0082	0.0272	CcSEcCtD
Methylnaltrexone—Injection site reaction—Docetaxel—melanoma	0.00799	0.0265	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Vemurafenib—melanoma	0.00728	0.0242	CcSEcCtD
Methylnaltrexone—Erythema—Bleomycin—melanoma	0.00626	0.0208	CcSEcCtD
Methylnaltrexone—Erythema—Dactinomycin—melanoma	0.00584	0.0194	CcSEcCtD
Methylnaltrexone—Diarrhoea—Vemurafenib—melanoma	0.00577	0.0192	CcSEcCtD
Methylnaltrexone—Dizziness—Vemurafenib—melanoma	0.00558	0.0185	CcSEcCtD
Methylnaltrexone—Erythema—Carmustine—melanoma	0.00547	0.0181	CcSEcCtD
Methylnaltrexone—Vomiting—Vemurafenib—melanoma	0.00536	0.0178	CcSEcCtD
Methylnaltrexone—Naltrexone—ABCB1—melanoma	0.00536	0.107	CrCbGaD
Methylnaltrexone—Erythema—Temozolomide—melanoma	0.00528	0.0175	CcSEcCtD
Methylnaltrexone—Oedema—Bleomycin—melanoma	0.00511	0.017	CcSEcCtD
Methylnaltrexone—Nausea—Vemurafenib—melanoma	0.00501	0.0166	CcSEcCtD
Methylnaltrexone—Oedema—Dactinomycin—melanoma	0.00477	0.0158	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00447	0.0148	CcSEcCtD
Methylnaltrexone—Oedema—Carmustine—melanoma	0.00446	0.0148	CcSEcCtD
Methylnaltrexone—Pain—Bleomycin—melanoma	0.00437	0.0145	CcSEcCtD
Methylnaltrexone—Oedema—Temozolomide—melanoma	0.00431	0.0143	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Temozolomide—melanoma	0.00423	0.014	CcSEcCtD
Methylnaltrexone—Skin disorder—Temozolomide—melanoma	0.00419	0.0139	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Temozolomide—melanoma	0.00417	0.0138	CcSEcCtD
Methylnaltrexone—Naloxone—ALB—melanoma	0.0041	0.0817	CrCbGaD
Methylnaltrexone—Pain—Dactinomycin—melanoma	0.00408	0.0135	CcSEcCtD
Methylnaltrexone—Buprenorphine—ABCB1—melanoma	0.00394	0.0786	CrCbGaD
Methylnaltrexone—Naloxone—ABCB1—melanoma	0.00391	0.078	CrCbGaD
Methylnaltrexone—Gastrointestinal pain—Dactinomycin—melanoma	0.0039	0.0129	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Carmustine—melanoma	0.00385	0.0128	CcSEcCtD
Methylnaltrexone—Pain—Carmustine—melanoma	0.00382	0.0127	CcSEcCtD
Methylnaltrexone—Abdominal pain—Dactinomycin—melanoma	0.00377	0.0125	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Temozolomide—melanoma	0.00372	0.0123	CcSEcCtD
Methylnaltrexone—Pain—Temozolomide—melanoma	0.00369	0.0122	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Carmustine—melanoma	0.00365	0.0121	CcSEcCtD
Methylnaltrexone—Abdominal pain—Carmustine—melanoma	0.00353	0.0117	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Temozolomide—melanoma	0.00353	0.0117	CcSEcCtD
Methylnaltrexone—Erythema—Docetaxel—melanoma	0.00351	0.0117	CcSEcCtD
Methylnaltrexone—Abdominal pain—Temozolomide—melanoma	0.00341	0.0113	CcSEcCtD
Methylnaltrexone—Diarrhoea—Dactinomycin—melanoma	0.00326	0.0108	CcSEcCtD
Methylnaltrexone—Vomiting—Bleomycin—melanoma	0.00325	0.0108	CcSEcCtD
Methylnaltrexone—Diarrhoea—Carmustine—melanoma	0.00305	0.0101	CcSEcCtD
Methylnaltrexone—Nausea—Bleomycin—melanoma	0.00304	0.0101	CcSEcCtD
Methylnaltrexone—Vomiting—Dactinomycin—melanoma	0.00303	0.0101	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.00297	0.00985	CcSEcCtD
Methylnaltrexone—Dizziness—Carmustine—melanoma	0.00295	0.00979	CcSEcCtD
Methylnaltrexone—Diarrhoea—Temozolomide—melanoma	0.00295	0.00979	CcSEcCtD
Methylnaltrexone—Oedema—Docetaxel—melanoma	0.00287	0.00951	CcSEcCtD
Methylnaltrexone—Dizziness—Temozolomide—melanoma	0.00285	0.00946	CcSEcCtD
Methylnaltrexone—Vomiting—Carmustine—melanoma	0.00284	0.00941	CcSEcCtD
Methylnaltrexone—Nausea—Dactinomycin—melanoma	0.00283	0.00939	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Docetaxel—melanoma	0.00281	0.00933	CcSEcCtD
Methylnaltrexone—Skin disorder—Docetaxel—melanoma	0.00279	0.00924	CcSEcCtD
Methylnaltrexone—Vomiting—Temozolomide—melanoma	0.00274	0.00909	CcSEcCtD
Methylnaltrexone—Nausea—Carmustine—melanoma	0.00265	0.00879	CcSEcCtD
Methylnaltrexone—Nausea—Temozolomide—melanoma	0.00256	0.0085	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Docetaxel—melanoma	0.00248	0.00821	CcSEcCtD
Methylnaltrexone—Pain—Docetaxel—melanoma	0.00245	0.00813	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Docetaxel—melanoma	0.00234	0.00778	CcSEcCtD
Methylnaltrexone—Abdominal pain—Docetaxel—melanoma	0.00227	0.00752	CcSEcCtD
Methylnaltrexone—Diarrhoea—Docetaxel—melanoma	0.00196	0.00651	CcSEcCtD
Methylnaltrexone—Dizziness—Docetaxel—melanoma	0.0019	0.00629	CcSEcCtD
Methylnaltrexone—Vomiting—Docetaxel—melanoma	0.00182	0.00605	CcSEcCtD
Methylnaltrexone—Nausea—Docetaxel—melanoma	0.0017	0.00565	CcSEcCtD
Methylnaltrexone—OPRM1—Signaling Pathways—CCR7—melanoma	0.000496	0.000764	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GRM1—melanoma	0.000496	0.000764	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CXCR2—melanoma	0.000486	0.000749	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CXCL8—melanoma	0.000486	0.000749	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SUFU—melanoma	0.000483	0.000745	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—RAC2—melanoma	0.000478	0.000737	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PRKCA—melanoma	0.000476	0.000734	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—WNT5A—melanoma	0.000471	0.000726	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—VEGFC—melanoma	0.000471	0.000726	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AKT3—melanoma	0.000464	0.000715	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—EDN1—melanoma	0.000461	0.000711	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—RHOB—melanoma	0.000451	0.000695	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—BCL2L11—melanoma	0.000451	0.000695	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CSF2—melanoma	0.000451	0.000695	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—RAC1—melanoma	0.000441	0.00068	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HDAC6—melanoma	0.000433	0.000668	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PRKCA—melanoma	0.000432	0.000666	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—EDN1—melanoma	0.000429	0.000662	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—MAP2K2—melanoma	0.000422	0.000651	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CSF2—melanoma	0.000419	0.000647	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—F2R—melanoma	0.000413	0.000637	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CXCR2—melanoma	0.000411	0.000633	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CXCL8—melanoma	0.00041	0.000633	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—RAC2—melanoma	0.000404	0.000623	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PRKCA—melanoma	0.000402	0.00062	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—RAC1—melanoma	0.000401	0.000618	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—EDNRB—melanoma	0.0004	0.000617	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—WNT5A—melanoma	0.000398	0.000613	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—VEGFC—melanoma	0.000398	0.000613	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—EDN1—melanoma	0.00039	0.000601	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PTK2B—melanoma	0.000388	0.000599	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CSF2—melanoma	0.000381	0.000587	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PLCB4—melanoma	0.000378	0.000583	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GAB2—melanoma	0.000378	0.000583	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GNA11—melanoma	0.000378	0.000583	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FLT1—melanoma	0.000376	0.00058	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—RAC1—melanoma	0.000373	0.000575	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CG—melanoma	0.000373	0.000575	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PRKCA—melanoma	0.000365	0.000563	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—MAP2K2—melanoma	0.000357	0.00055	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SLC6A11—melanoma	0.000355	0.000548	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIP4K2A—melanoma	0.000355	0.000548	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HDAC2—melanoma	0.000355	0.000548	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FOXO4—melanoma	0.000355	0.000548	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CXCR4—melanoma	0.000355	0.000548	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GNAQ—melanoma	0.000351	0.000542	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—F2R—melanoma	0.000349	0.000538	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—MTAP—melanoma	0.000346	0.000533	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—RAC1—melanoma	0.000338	0.000522	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CG—melanoma	0.000338	0.000522	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EDNRB—melanoma	0.000338	0.000521	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SYK—melanoma	0.00033	0.000509	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PTK2B—melanoma	0.000328	0.000506	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CD—melanoma	0.000328	0.000505	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ITGAV—melanoma	0.000324	0.0005	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NGFR—melanoma	0.000324	0.0005	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AKT3—melanoma	0.000324	0.0005	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GAB2—melanoma	0.000319	0.000492	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GNA11—melanoma	0.000319	0.000492	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FLT1—melanoma	0.000318	0.00049	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CG—melanoma	0.000315	0.000486	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PHGDH—melanoma	0.000308	0.000475	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—LUM—melanoma	0.000308	0.000475	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HPSE—melanoma	0.000302	0.000466	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CXCR4—melanoma	0.0003	0.000463	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HDAC2—melanoma	0.0003	0.000463	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FOXO4—melanoma	0.0003	0.000463	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SOCS1—melanoma	0.0003	0.000463	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—MAP2K1—melanoma	0.000299	0.000462	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—S100B—melanoma	0.000299	0.000462	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CD—melanoma	0.000297	0.000459	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GNAQ—melanoma	0.000297	0.000458	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CUBN—melanoma	0.000297	0.000457	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SDHD—melanoma	0.000286	0.000442	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CSPG4—melanoma	0.000286	0.000442	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—BSG—melanoma	0.000286	0.000442	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ERBB4—melanoma	0.000286	0.000442	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CG—melanoma	0.000286	0.000441	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CB—melanoma	0.000286	0.00044	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CDKN2B—melanoma	0.000284	0.000438	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SYK—melanoma	0.000279	0.00043	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GPAM—melanoma	0.000277	0.000428	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CD—melanoma	0.000277	0.000427	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CD86—melanoma	0.000275	0.000423	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CXCL8—melanoma	0.000274	0.000423	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ITGAV—melanoma	0.000274	0.000423	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NGFR—melanoma	0.000274	0.000423	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AKT3—melanoma	0.000274	0.000423	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—EDN1—melanoma	0.000272	0.00042	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FGF1—melanoma	0.000266	0.000411	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CSF2—melanoma	0.000266	0.000411	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—IL2—melanoma	0.000262	0.000404	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—E2F1—melanoma	0.00026	0.000402	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CB—melanoma	0.000259	0.0004	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PDGFRA—melanoma	0.000258	0.000398	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ITGB3—melanoma	0.000255	0.000394	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PRKCA—melanoma	0.000255	0.000394	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SOCS1—melanoma	0.000254	0.000391	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—MAP2K1—melanoma	0.000253	0.00039	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—S100B—melanoma	0.000253	0.00039	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CD—melanoma	0.000251	0.000388	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SPP1—melanoma	0.00025	0.000386	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MAP2K2—melanoma	0.000249	0.000385	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CXCL8—melanoma	0.000249	0.000384	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ERBB4—melanoma	0.000242	0.000373	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CB—melanoma	0.000241	0.000372	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CDKN2B—melanoma	0.00024	0.00037	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IL2—melanoma	0.000238	0.000367	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TERT—melanoma	0.000237	0.000366	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—RAC1—melanoma	0.000237	0.000365	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PLA2G6—melanoma	0.000236	0.000364	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CD86—melanoma	0.000232	0.000358	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CXCL8—melanoma	0.000232	0.000358	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EDN1—melanoma	0.00023	0.000355	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HIF1A—melanoma	0.000227	0.00035	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CSF2—melanoma	0.000225	0.000347	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FGF1—melanoma	0.000225	0.000347	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—IL2—melanoma	0.000222	0.000342	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—E2F1—melanoma	0.00022	0.00034	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CB—melanoma	0.000219	0.000338	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PDGFRA—melanoma	0.000218	0.000336	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—KDR—melanoma	0.000217	0.000335	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PRKCA—melanoma	0.000216	0.000333	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ITGB3—melanoma	0.000216	0.000333	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—VCAN—melanoma	0.000212	0.000327	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SPP1—melanoma	0.000212	0.000326	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MAP2K2—melanoma	0.000211	0.000325	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CXCL8—melanoma	0.000211	0.000325	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FN1—melanoma	0.000209	0.000322	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NOTCH1—melanoma	0.000204	0.000315	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL2—melanoma	0.000201	0.00031	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TERT—melanoma	0.000201	0.000309	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CD80—melanoma	0.0002	0.000309	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—RAC1—melanoma	0.0002	0.000308	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CG—melanoma	0.0002	0.000308	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—KIT—melanoma	0.0002	0.000308	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—APC—melanoma	0.0002	0.000308	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—NRAS—melanoma	0.0002	0.000308	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—EGF—melanoma	0.000198	0.000305	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HIF1A—melanoma	0.000192	0.000296	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—MAPK3—melanoma	0.000191	0.000295	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—BRAF—melanoma	0.000188	0.00029	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—KDR—melanoma	0.000183	0.000283	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IGF1—melanoma	0.000183	0.000282	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—MAPK1—melanoma	0.000182	0.000281	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—EGFR—melanoma	0.000182	0.000281	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP17A1—melanoma	0.000179	0.000276	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MAP2K1—melanoma	0.000177	0.000273	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FN1—melanoma	0.000177	0.000272	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CD—melanoma	0.000176	0.000271	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CA—melanoma	0.000174	0.000268	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NOTCH1—melanoma	0.000173	0.000266	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—KRAS—melanoma	0.000172	0.000265	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CD80—melanoma	0.000169	0.000261	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CG—melanoma	0.000169	0.000261	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—KIT—melanoma	0.000169	0.000261	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—APC—melanoma	0.000169	0.000261	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—NRAS—melanoma	0.000169	0.000261	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GNA11—melanoma	0.000169	0.00026	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FGF2—melanoma	0.000168	0.000259	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EGF—melanoma	0.000167	0.000258	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—FASN—melanoma	0.000165	0.000255	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SLC5A5—melanoma	0.000162	0.000251	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—MAPK3—melanoma	0.000162	0.00025	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—BRAF—melanoma	0.000159	0.000245	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CA—melanoma	0.000158	0.000244	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MDM2—melanoma	0.000157	0.000243	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GNAQ—melanoma	0.000157	0.000242	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CD44—melanoma	0.000157	0.000242	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ERBB2—melanoma	0.000155	0.000239	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IGF1—melanoma	0.000155	0.000239	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—MAPK1—melanoma	0.000154	0.000237	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—EGFR—melanoma	0.000154	0.000237	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CB—melanoma	0.000153	0.000236	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP1B1—melanoma	0.00015	0.000232	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MAP2K1—melanoma	0.00015	0.000231	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CD—melanoma	0.000149	0.000229	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CXCL8—melanoma	0.000147	0.000227	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CA—melanoma	0.000147	0.000227	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—HRAS—melanoma	0.000146	0.000226	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—KRAS—melanoma	0.000145	0.000224	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CDKN1B—melanoma	0.000144	0.000222	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FGF2—melanoma	0.000142	0.000219	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—AKT1—melanoma	0.000142	0.000219	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CASP3—melanoma	0.000141	0.000217	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL2—melanoma	0.000141	0.000217	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IL6—melanoma	0.00014	0.000216	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCND1—melanoma	0.000137	0.000211	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CTNNB1—melanoma	0.000136	0.000209	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CA—melanoma	0.000134	0.000206	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MMP9—melanoma	0.000133	0.000205	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MDM2—melanoma	0.000133	0.000205	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CDKN1A—melanoma	0.000133	0.000205	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PTEN—melanoma	0.000132	0.000204	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NFKB1—melanoma	0.000132	0.000203	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ERBB2—melanoma	0.000131	0.000202	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CB—melanoma	0.000129	0.0002	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—AKT1—melanoma	0.000129	0.000199	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CXCL8—melanoma	0.000124	0.000192	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ABCB1—melanoma	0.000124	0.000191	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—HRAS—melanoma	0.000124	0.000191	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CDKN1B—melanoma	0.000121	0.000187	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—AKT1—melanoma	0.00012	0.000185	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—VEGFA—melanoma	0.00012	0.000184	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CASP3—melanoma	0.000119	0.000184	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL2—melanoma	0.000119	0.000183	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—STAT3—melanoma	0.000118	0.000183	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL6—melanoma	0.000118	0.000182	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NRAS—melanoma	0.000118	0.000182	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCND1—melanoma	0.000116	0.000179	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CTNNB1—melanoma	0.000115	0.000177	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PRKCA—melanoma	0.000114	0.000176	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ERCC2—melanoma	0.000113	0.000174	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MAPK3—melanoma	0.000113	0.000174	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MMP9—melanoma	0.000113	0.000174	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CDKN1A—melanoma	0.000112	0.000173	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PTEN—melanoma	0.000112	0.000173	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NFKB1—melanoma	0.000111	0.000172	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MYC—melanoma	0.00011	0.00017	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AKT1—melanoma	0.000109	0.000168	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MAPK1—melanoma	0.000108	0.000166	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—EGFR—melanoma	0.000108	0.000166	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—KRAS—melanoma	0.000102	0.000157	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—VEGFA—melanoma	0.000101	0.000156	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—STAT3—melanoma	0.0001	0.000154	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NRAS—melanoma	9.98e-05	0.000154	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MAPK3—melanoma	9.56e-05	0.000147	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CA—melanoma	9.34e-05	0.000144	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MYC—melanoma	9.3e-05	0.000143	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MAPK1—melanoma	9.09e-05	0.00014	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EGFR—melanoma	9.09e-05	0.00014	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TP53—melanoma	9.03e-05	0.000139	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CG—melanoma	8.93e-05	0.000138	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HRAS—melanoma	8.64e-05	0.000133	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PPARG—melanoma	8.62e-05	0.000133	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—KRAS—melanoma	8.59e-05	0.000132	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL6—melanoma	8.27e-05	0.000128	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CA—melanoma	7.89e-05	0.000122	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CD—melanoma	7.85e-05	0.000121	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ALB—melanoma	7.75e-05	0.00012	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TP53—melanoma	7.63e-05	0.000118	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AKT1—melanoma	7.63e-05	0.000118	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HRAS—melanoma	7.3e-05	0.000113	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL6—melanoma	6.99e-05	0.000108	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CB—melanoma	6.84e-05	0.000106	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PTGS2—melanoma	6.78e-05	0.000105	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AKT1—melanoma	6.45e-05	9.94e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PTEN—melanoma	5.91e-05	9.12e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CA—melanoma	4.17e-05	6.43e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—AKT1—melanoma	3.41e-05	5.26e-05	CbGpPWpGaD
